Assyro AI

FDA Orange Book · active-ingredient family

Sodium iodide i-131

Sodium iodide i-131 is approved as 6 brand and 2 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

Reference-listed drug:SODIUM IODIDE I 131 · NDA 021305

6

Brand (NDA)

2

Generics (ANDA)

0

Listed patents

0

Exclusivity periods

Brand (NDA) products · capsule, solution

ProductApplicantApplicationTEApproved
SODIUM IODIDE I 131RLD×6JUBILANTNDA 021305May 19, 2005
SODIUM IODIDE I 131RLD×2CURIUMNDA 016515Approved Prior to Jan 1, 1982
SODIUM IODIDE I 131RLD×2CURIUMNDA 016517Approved Prior to Jan 1, 1982
IODOTOPE×3BRACCONDA 010929Approved Prior to Jan 1, 1982
SODIUM IODIDE I 131×2CISNDA 017316Approved Prior to Jan 1, 1982
SODIUM IODIDE I 131SUN PHARM INDS INCNDA 017315Approved Prior to Jan 1, 1982

Generic (ANDA) products (2)

ProductApplicantApplicationTEApproved
SODIUM IODIDE I 131CARDINAL HLTH 414ANDA 213615Jun 12, 2025
SODIUM IODIDE I 131INTL ISOTOPESANDA 209166AAFeb 05, 2020

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Sodium iodide i-131 — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.